Velocity Clinical Research-Savannah

Savannah, Georgia 31419

7 studies enrolling now · 26 studies all time

What they study most

Acute Gastroenteritis, Atherosclerotic Cardiovascular Disease, COVID-19, COVID-19 Infection, COVID-19 SARS-CoV-2 Infection, Chronic Kidney Disease, Clostridioides Difficile Associated Disease, Diabetic Peripheral Neuropathic Pain, Epstein-Barr Virus Infection, Healthy Volunteers, Influenza, Influenza, Human

Studies at this site

• A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised — Recruiting now
• A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease — Recruiting now
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Recruiting now
• Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) — Recruiting now
• Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy — Recruiting now
• A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older — Recruiting now
• A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults — Recruiting now
• A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes — Completed
• A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults — Completed
• A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection — Running, not enrolling
• A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis — Running, not enrolling
• A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults — Running, not enrolling
• A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age — Completed
• A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) — Running, not enrolling
• Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS — Stopped early
• Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) — Running, not enrolling
• Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine — Completed
• A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age — Completed
• Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. — Running, not enrolling
• Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D). — Stopped early
• Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR) — Completed
• A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age — Completed
• Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults — Completed
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza — Completed
• Study of mRNA-1010 Seasonal Influenza Vaccine in Adults — Completed
• A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older — Completed